Texas Permanent School Fund Corp Raises Holdings in Artivion, Inc. (NYSE:AORT)

Texas Permanent School Fund Corp lifted its stake in Artivion, Inc. (NYSE:AORT) by 14.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 39,063 shares of the company’s stock after purchasing an additional 4,934 shares during the quarter. Texas Permanent School Fund Corp owned about 0.09% of Artivion worth $1,002,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC increased its stake in Artivion by 38.6% during the 1st quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock valued at $38,000 after purchasing an additional 505 shares in the last quarter. Louisiana State Employees Retirement System grew its holdings in shares of Artivion by 3.1% during the second quarter. Louisiana State Employees Retirement System now owns 19,900 shares of the company’s stock valued at $510,000 after buying an additional 600 shares during the last quarter. nVerses Capital LLC acquired a new position in shares of Artivion in the 2nd quarter valued at $28,000. Price T Rowe Associates Inc. MD raised its stake in Artivion by 5.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,690 shares of the company’s stock worth $713,000 after acquiring an additional 1,634 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Artivion by 0.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 301,992 shares of the company’s stock worth $7,746,000 after acquiring an additional 2,018 shares during the period. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Artivion Stock Up 0.3 %

Shares of AORT opened at $25.21 on Friday. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of -105.04 and a beta of 1.74. Artivion, Inc. has a 52 week low of $12.16 and a 52 week high of $29.24. The stock’s 50-day moving average price is $26.03 and its 200-day moving average price is $23.64. The company has a quick ratio of 4.04, a current ratio of 5.63 and a debt-to-equity ratio of 1.07.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.03 by $0.04. The business had revenue of $98.02 million for the quarter, compared to analyst estimates of $97.70 million. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. On average, sell-side analysts predict that Artivion, Inc. will post 0.2 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on AORT shares. Needham & Company LLC reissued a “buy” rating and issued a $30.00 price objective on shares of Artivion in a report on Friday, August 9th. Lake Street Capital increased their price target on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Stifel Nicolaus lifted their price objective on shares of Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, September 13th. Finally, Oppenheimer increased their price objective on shares of Artivion from $25.00 to $30.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th.

Insider Buying and Selling

In other Artivion news, Director Anthony B. Semedo sold 9,709 shares of Artivion stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $24.99, for a total value of $242,627.91. Following the completion of the transaction, the director now owns 34,159 shares of the company’s stock, valued at $853,633.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, SVP Jean F. Holloway sold 3,167 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $26.55, for a total transaction of $84,083.85. Following the completion of the transaction, the senior vice president now directly owns 161,932 shares of the company’s stock, valued at approximately $4,299,294.60. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Anthony B. Semedo sold 9,709 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $24.99, for a total value of $242,627.91. Following the transaction, the director now owns 34,159 shares in the company, valued at approximately $853,633.41. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,679 shares of company stock valued at $626,518. Corporate insiders own 8.10% of the company’s stock.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.